Results 81 to 90 of about 57,115 (246)

The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis [PDF]

open access: yes, 2015
OBJECTIVE The treatment of lupus nephritis is still an unmet medical need requiring new therapeutic approaches. Our group found recently that irinotecan, an inhibitor of topoisomerase I (topo I), reversed proteinuria and prolonged survival in mice ...
Keil, Andreas   +11 more
core   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue   +6 more
wiley   +1 more source

Advances in Immunological Combination Therapy for Colorectal Cancer

open access: yesiMetaMed, EarlyView.
Review the progress of combined immunotherapy for colorectal cancer. ABSTRACT Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration.
Jiayue Wu   +7 more
wiley   +1 more source

Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review

open access: yesPharmaceutics
Background/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 ...
Xando Díaz-Villamarín   +9 more
doaj   +1 more source

Impact of Neoadjuvant Approach and Tumor Response on Survival in Pancreatic Adenocarcinoma

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Introduction Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single‐agent to multi‐agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We hypothesized
Mohammed O. Suraju   +9 more
wiley   +1 more source

Precise delineation of radiation targets for thoracic tumors in the immunotherapy era: from immune mechanisms to clinical practice

open access: yesPrecision Radiation Oncology, EarlyView.
RT‐immunotherapy synergy for thoracic tumors relies on precise target delineation to protect immune components. IFI, reduced volumes, and optimized positioning minimize damage, while multimodal imaging, DL, PBT, and FLASH‐RT enhance control. These innovations shift RT to an immune‐centric model, improving lung and esophageal cancer outcomes.
Xiaoying Chen   +3 more
wiley   +1 more source

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit   +5 more
wiley   +1 more source

Sensing‐Integrated Patient‐Derived Tumorspheres Predict Chemotherapeutic Efficacy via Local Extracellular pH Dynamics

open access: yesSmall, EarlyView.
The study introduces a 3D sensing‐integrated platform enabling real‐time, non‐invasive monitoring of pH dynamics in patient‐derived PDAC tumorspheres. It revealed distinct extracellular acidification patterns under FOLFIRINOX, gemcitabine, and paclitaxel, correlating with therapeutic efficacy.
Stefania Forciniti   +10 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

open access: yesSmart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou   +4 more
wiley   +1 more source

Modulation of irinotecan metabolism by ketoconazole

open access: yes, 2002
PURPOSE: Irinotecan (CPT-11) is a prodrug of SN-38 and has been registered for the treatment of advanced colorectal cancer. It is converted by the cytochrome P450 3A4 isozyme (CYP3A4) into several inactive metabolites, including 7-ethyl-10-[4-N-(5 ...
Mathijssen, RHJ; id_orcid   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy